Physician profile
Mitzi Bray
NPI 1912266883
$7,553.19
in general payments reported to CMS, 2019-2025
28 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $921 · 2022: $1,048 · 2023: $1,597 · 2024: $2,131 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,461 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,461.13 |
| Education | $123.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,508.55 | 2021-2025 | |
| Janssen Biotech, INC. | $623.24 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Incyte Corporation | $550.12 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $549.21 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $477.14 | 2022-2025 | Sotyktu |
| Amgen INC. | $468.60 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $423.99 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $384.79 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $368.34 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $350.47 | 2021-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $328.28 | 2021-2025 | |
| Galderma Laboratories, L.P. | $283.35 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $258.46 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $249.78 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.15 | 2023-2025 | Spevigo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $130.24 | 2021-2025 | Taltz, Ebglyss |
| Biofrontera INC. | $109.62 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $83.26 | 2021 | |
| Almirall LLC | $79.51 | 2022-2025 | Klisyri |
| Krystal Biotech INC | $27.82 | 2023 | Vyjuvek |
| Medline Industries Lp | $23.00 | 2023 | |
| Organogenesis INC. | $19.62 | 2023 | Puraply |
| Botanix Sb INC | $18.95 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.97 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.84 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $15.89 | 2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $13.83 | 2023 | Valchlor |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitzi Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.